RecruitingNot ApplicableNCT05538910

Defining Neurobiological Links Between Substance Use and Mental Illness


Sponsor

National Institute on Drug Abuse (NIDA)

Enrollment

620 participants

Start Date

Feb 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brain function. Eligibility: People aged 18 to 60 years, at the time of consent, with and without MDD who do not smoke cigarettes or use other nicotine products. Design: Participants will have 2 or 3 study visits over 1 year. Participants will have 2 MRI scans no less than 4 days apart. Each scan visit will last 5 to 7 hours. At each scan, they will have urine and breath tests to screen for recent use of alcohol, nicotine, and illegal drugs. Before each scan, they will take 1 of 2 medications: nicotine or placebo. Participants will receive each medication once. They will not know which medication they are receiving at each scan. For each MRI scan, they will lie on a table that slides into a cylinder. Sometimes they will be asked to lie still. Sometimes they will complete tasks on a computer. Tasks may include identifying colors or playing games to win money. Each scan will take about 2 hours. Participants will answer questions about their thoughts, feelings, and behaviors before and after each scan. They will have a blood test after each scan.


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This research study at the National Institute on Drug Abuse (NIDA) is investigating the brain biology that connects substance use disorders (such as addiction to alcohol, opioids, or stimulants) with mental illness (such as depression, anxiety, or psychosis). Participants undergo brain imaging, cognitive testing, and other assessments to help researchers understand how these conditions overlap and influence each other. **You may be eligible if:** - You are evaluated and found eligible through the NIDA screening process - You have a history of substance use and/or a mental health condition (or are a healthy volunteer) - You are willing to participate in brain scans and assessments at the NIDA research facility **You may NOT be eligible if:** - You do not meet the NIDA screening criteria - You have medical or psychiatric conditions that would make the study procedures unsafe - You are unable or unwilling to travel to the NIDA facility for assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPlacebo Nicotine Patch

Comparator

DRUGNicotine Patch

Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner


Locations(1)

National Institute on Drug Abuse

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05538910


Related Trials